“317护”宣教平台联合肠道准备评估单在结肠镜检查前的应用

目的评价“317护”宣教平台联合肠道准备评估单在肠镜检查前的应用效果。方法选取2020年10月-2021年1月我科行结肠镜检查的住院患者120例为研究对象。根据住院时间分为观察组和对照组,各60例。观察组实施“317护”宣教平台联合肠道准备评估单进行肠道准备,对照组使用肠道准备评估单进行肠道准备。比较两组肠道清洁度、肠道清洁剂服用方法正确率、肠道准备满意度。结果观察组肠道清洁度评分、肠道清洁剂服用方法正确率及肠道准备满意度高于对照组(P<0.05)。结论应用“317护”宣教平台联合肠道准备评估单在肠镜检查前进行健康宣教后,提高了患者肠道清洁度、肠道清洁剂服用方法正确率及肠道准备满意度。     

Treatment of metachronous colorectal cancer metastases in the Netherlands: A population-based study

BackgroundThis study aimed to describe the treatment of metachronous colorectal cancer metastases in a recent population-based cohort.MethodPatients with stage I-III colorectal cancer (CRC), diagnosed between January 1st and June 30th^, 2015 who were surgically treated with curative intent were selected from the Netherlands Cancer Registry. Follow-up was at least 3 years after diagnosis of the primary tumour. Treatment of metachronous metastases was categorized into local treatment, systemic treatment, and best supportive care. Overall survival was estimated using Kaplan-Meier method.ResultsOut of 5412 patients, 782 (14%) developed metachronous metastases, of whom 393 (50%) underwent local treatment (LT) with or without systemic therapy, 30% of patients underwent only systemic therapy (ST) and 19% only best supportive care (BSC). The most common metastatic site was the liver (51%) followed by lungs (33%) and peritoneum (22%). LT rates were 69%, 66%, and 44% for liver-only, lung-only and, peritoneal-only metastases respectively. Patients receiving LT and ST were significantly younger than patients receiving LT alone, while patients receiving BSC were significantly older than the other groups (p < 0.001). Patients with liver-only or lung-only metastases had a 3-year OS of 50.2% (43.3–56.7 95% CI) and 61.5% (50.7–70.6 95% CI) respectively. Patients with peritoneal-only disease had a lower 3-year OS, 18.1% (10.1–28.0 95% CI).ConclusionPatients with metastases confined to the liver and lung have the highest rates of local treatment for metachronous metastatic colorectal cancer. The number of patients who underwent local treatment is higher than reported in previous Dutch and international studies.     

Fourteen years of the Pregnancy Registry on maternal immunisation with a reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap) vaccine

BackgroundGSK initiated a Pregnancy Registry in the United States (US) for the reduced-antigen-content tetanus-diphtheria-acellular pertussis (Tdap; Boostrix, GSK) vaccine with the aim to detect and describe pregnancy outcomes in women vaccinated with Boostrix 28 days before estimated conception or during pregnancy.MethodsVoluntary reports of pregnancy exposure to Boostrix received from spontaneous and post-marketing surveillance sources in the US were assessed. Reports were classified as prospective or retrospective based on the knowledge of pregnancy outcomes at the time of reporting. For completeness, reports of exposure to Boostrix or to the Tdap-inactivated poliovirus vaccine (Boostrix-IPV, GSK) reported to the global safety database from countries outside the US were also evaluated.ResultsFrom May 2005 to August 2019, 1517 (1455 prospective and 62 retrospective) pregnancy reports were received in the Boostrix US Pregnancy Registry. Of the prospective reports, 250 had known outcomes: 244 live infants with no apparent birth defects (BDs), three live infants with BDs, and three spontaneous abortions with no apparent BDs. Of the retrospective reports, 55 had known outcomes: 33 live infants with no apparent BDs, 16 live infants with BDs, one spontaneous abortion with no apparent BDs, four stillbirths with no apparent BDs, and one stillbirth with BDs. Cumulatively, 1321 pregnancy reports (1006 for Boostrix; 315 for Boostrix-IPV) were received from countries outside the US. Of these, 163 prospective reports and 551 retrospective reports had known outcomes. Results were in line with those from the Boostrix US Pregnancy Registry.ConclusionsData currently available from the Boostrix US Pregnancy Registry and from countries outside the US suggested that exposure to Boostrix or Boostrix-IPV during pregnancy does not raise safety concerns related to adverse pregnancy outcomes or BDs.     

新时代检验医学发展定位与思考

检验医学作为医学科学的重要支撑学科,在疾病早期诊断、病情监测、预后判断与风险评估等方面发挥着重要作用。21世纪是数字信息时代,高新检测技术、计算机科学及互联网大数据等,为检验医学的发展带来巨大的机遇与挑战,新时代下如何借助信息科技革命实现检验医学新发展是检验工作者面临的重要课题。该文回顾检验医学的发展历程,重点关注检验医学在新时代的发展定位及未来发展方向,以求开创检验医学发展新局面。     

微视频联合微信在《神经病学》教学中的应用

目的研究微视频课堂播放联合课后微信平台共享教学模式在《神经病学》应用的教学效果。方法将《神经病学》教学任务中常见疾病的症状、体征及诊疗录制成微小视频,将预防医学和临床医学专业的22个班级随机分成对照组和试验组,分别进行常规模式教学和常规模式结合微视频课堂播放联合课后微信平台共享教学模式,通过理论考试、病案分析、文献检索能力及问卷调查方式综合评估教学效果。结果与对照组比较,试验组小考试及典型病案分析成绩的及格率、优秀率及平均分均提高(P<0.05)。试验组最终考试的及格率更高(P<0.05),差异具有统计学意义;两组最终考试的优秀率差异无统计学意义(P>0.05);试验组平均分更高(P<0.05)。结论微视频课堂播放联合课后微信平台共享教学模式在《神经病学》教学中的应用具有良好的教学效果。     

基于“317护”健教平台的慢性肝病患者健康教育效果评价

目的探讨"317护"健教平台在住院的慢性肝病患者健康教育应用中的临床效果。方法选择2018年1～6月我院170例15～65周岁的住院患者为研究对象,采用随机数字表法等分为观察组和对照组,对照组由责任护士进行常规面对面的健康教育指导,观察组采用"317护"微信平台开展健康教育,比较两组患者对入院须知、疾病知识、治疗方法、检查须知、药物知识、饮食指导、出院指导等知识的掌握程度,两组患者对所获健康知识方式的满意度。结果观察组患者对入院须知、疾病知识、药物知识、饮食指导等的知晓率达93.95%,知识掌握程度明显高于对照组的81.18%,差异有统计学意义(P0.05),观察组患者对健康教育的满意度高于对照组,差异有统计学意义(P0.05)。结论结合"317护"健教平台的管理模式,能提高患者对健康教育知识的知晓率,促进患者对疾病的自我管理,提高其对护理工作的满意度。     

基于二维码的电子诊疗卡系统的设计

目的构建一个以二维码作为电子诊疗卡替代医院传统诊疗卡的系统。方法依托医院微医疗平台,对患者唯一标识和时间戳进行MD5计算生成字符串,并以此内容生成二维码作为电子诊疗卡,同时对HIS进行相应改造,实现电子诊疗卡在全院的应用。结果利用时间戳和MD5签名生成二维码保证了电子诊疗卡加密的唯一性、时效性,医院每年节约成本5万元,患者每次就诊时间减少5 min,提升了患者满意度。结论本文构建的二维码电子诊疗卡系统,解决了使用实体诊疗卡过程中经常出现的忘带卡和重复办卡等问题,提高了医院服务质量,改善了患者就医体验。     

2014年山西省肿瘤登记地区恶性肿瘤发病与死亡分析

目的探讨2014年山西省肿瘤登记地区恶性肿瘤发病与死亡情况。方法收集2014年全省12个肿瘤登记地区的数据资料,分析不同地区、不同年龄和性别的恶性肿瘤发病率与死亡率特点,同时与全国数据进行比较。结果2014年山西省肿瘤登记地区新发恶性肿瘤11703例(男性6559例,女性5144例),发病率为221.21/10万,中国人口标化发病率为163.91/10万,世界人口标化发病率为163.25/10万;城市地区发病率、中国人口标化发病率分别为247.02/10万、171.35/10万,农村地区分别为205.98/10万、159.03/10万。男性常见恶性肿瘤发病以胃癌、肺癌、食管癌、肝癌、结直肠癌为主,女性以乳腺癌、子宫颈癌、肺癌、食管癌、胃癌为主。恶性肿瘤死亡病例7283例(男性4548例,女性2735例),恶性肿瘤死亡率为137.66/10万,中国人口标化死亡率为99.67/10万,世界人口标化死亡率为100.11/10万;城市地区死亡率、中国人口标化死亡率分别为141.03/10万、92.84/10万,农村地区分别为135.68/10万、103.69/10万。男性常见恶性肿瘤死亡以肺癌、胃癌、肝癌、食管癌、结直肠癌为主,女性以肺癌、胃癌、肝癌、食管癌、子宫颈癌为主。结论山西省肿瘤登记地区恶性肿瘤发病与死亡均以肺癌、上消化道恶性肿瘤和女性子宫颈癌为主,胃癌、子宫颈癌的发病率较高。     

The prognostic relevance of histologic subtype in appendiceal adenocarcinoma

BackgroundThe aim of this population-based study was to determine the prognostic value of the histologic subtypes mucinous (MAC), non-mucinous (AC) and signet ring cell (SRCC) adenocarcinoma among patients with appendiceal cancer.Methods and materialsData from the Netherlands Cancer Registry (NCR) of patients with primary appendiceal adenocarcinomas with MAC, AC and SRCC histologic subtype, diagnosed between 2001 and 2015 were used (n = 675). To categorize patients according to the recent histopathological classification, the NCR was linked with the Dutch Pathology Registry (PALGA). Log-rank tests and Kaplan-Meier analyses were performed to estimate overall survival (OS), and the cox proportional hazards model was run to identify prognostic factors.ResultsAC was the most frequently encountered histologic subtype (50.9%), followed by MAC (35.8%) and SRCC (13.3%). In locoregional disease, histologic subtype was not a prognostic factor for OS with 5-year survival rates for patients with AC, MAC and SRCC of 60.0%, 60.5% and 69.6% respectively (p = 0.68). Metastatic disease was more common in SRCC (53.8%) than in MAC (38.8%) and AC (23.4%) (p < 0.0001). Median OS for patients with metastatic disease was 12.6, 27.7 and 18.2 months in AC, MAC and SRCC respectively (p < 0.005). MAC was associated with higher survival compared to AC (HR 0.48, 95%CI 0.34–0.69). In subanalyses, MAC was only a positive prognostic factor compared to AC in patients with peritoneal metastases (HR 0.42, 95%CI 0.28–0.62).ConclusionHistologic subtype had no prognostic relevance in locoregional or systemic metastatic disease in appendiceal adenocarcinoma. In peritoneal metastases, mucinous histologic subtype was a favorable prognostic factor, compared to non-mucinous and signet ring cell subtype.